Mineralys Therapeutics, Inc., a biopharmaceutical firm listed on Nasdaq under the ticker symbol MLYS, has disclosed the presentation of five abstracts at the 2026 American Heart Association (AHA) Hypertension Scientific Sessions in Arlington, VA from October 7-11. The company specializes in developing medications to address hypertension and aldosterone-related adverse effects in concurrent illnesses like chronic kidney disease, obstructive sleep apnea (OSA), and other ailments triggered by dysregulated aldosterone.